Xponance Inc. Lowers Holdings in Teleflex Incorporated (NYSE:TFX)

Xponance Inc. trimmed its position in Teleflex Incorporated (NYSE:TFX) by 10.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,042 shares of the medical technology company’s stock after selling 738 shares during the quarter. Xponance Inc.’s holdings in Teleflex were worth $1,507,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in TFX. National Bank of Canada FI lifted its holdings in shares of Teleflex by 28.1% in the 3rd quarter. National Bank of Canada FI now owns 10,049 shares of the medical technology company’s stock worth $1,969,000 after buying an additional 2,202 shares during the period. GHP Investment Advisors Inc. raised its position in shares of Teleflex by 18.7% in the 3rd quarter. GHP Investment Advisors Inc. now owns 7,919 shares of the medical technology company’s stock worth $1,501,000 after acquiring an additional 1,246 shares in the last quarter. Exchange Traded Concepts LLC raised its position in shares of Teleflex by 157.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 273 shares of the medical technology company’s stock worth $54,000 after acquiring an additional 167 shares in the last quarter. LGT Capital Partners LTD. raised its position in shares of Teleflex by 12.2% in the 3rd quarter. LGT Capital Partners LTD. now owns 66,914 shares of the medical technology company’s stock worth $13,143,000 after acquiring an additional 7,266 shares in the last quarter. Finally, Boston Trust Walden Corp raised its position in shares of Teleflex by 0.4% in the 3rd quarter. Boston Trust Walden Corp now owns 193,788 shares of the medical technology company’s stock worth $38,062,000 after acquiring an additional 749 shares in the last quarter. 95.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Teleflex

In other Teleflex news, VP Cameron P. Hicks sold 7,401 shares of the firm’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $225.00, for a total transaction of $1,665,225.00. Following the completion of the sale, the vice president now owns 10,050 shares of the company’s stock, valued at $2,261,250. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 1.43% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. StockNews.com lowered Teleflex from a “buy” rating to a “hold” rating in a research report on Friday, February 23rd. Royal Bank of Canada reduced their price target on Teleflex from $272.00 to $265.00 and set an “outperform” rating for the company in a research report on Friday, February 23rd. Truist Financial reduced their price target on Teleflex from $270.00 to $265.00 and set a “hold” rating for the company in a research report on Friday, February 23rd. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $285.00 target price on shares of Teleflex in a research report on Friday, February 23rd. Five analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, Teleflex currently has an average rating of “Moderate Buy” and an average target price of $267.50.

Teleflex Stock Performance

Shares of TFX stock opened at $211.18 on Wednesday. The company has a market capitalization of $9.95 billion, a P/E ratio of 28.05, a P/E/G ratio of 1.98 and a beta of 1.11. The business’s 50 day moving average is $223.84 and its two-hundred day moving average is $225.76. The company has a current ratio of 2.32, a quick ratio of 1.29 and a debt-to-equity ratio of 0.39. Teleflex Incorporated has a 12-month low of $177.63 and a 12-month high of $276.43.

Teleflex (NYSE:TFX) last announced its earnings results on Thursday, February 22nd. The medical technology company reported $3.38 EPS for the quarter, beating analysts’ consensus estimates of $3.26 by $0.12. Teleflex had a return on equity of 14.98% and a net margin of 11.98%. The business had revenue of $773.90 million during the quarter, compared to analysts’ expectations of $769.01 million. During the same quarter in the prior year, the firm earned $3.52 earnings per share. The business’s revenue was up 2.1% compared to the same quarter last year. Analysts expect that Teleflex Incorporated will post 13.73 EPS for the current fiscal year.

Teleflex Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 15th. Investors of record on Friday, March 1st were issued a $0.34 dividend. The ex-dividend date of this dividend was Thursday, February 29th. This represents a $1.36 annualized dividend and a dividend yield of 0.64%. Teleflex’s dividend payout ratio is presently 18.06%.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.